Get started
Author

Inès Doghri

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS
2024 · Guillaume Jouvenot, Guilhem Courbon, et al. · JAMA Neurology · 66
PDF
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
2024 · Nail Benallegue, Fabien Rollot, et al. · JAMA Neurology · 48
PDF
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis
2024 · Antoine Gavoille, Fabien Rollot, et al. · JAMA Neurology · 34
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis
2025 · Antoine Gavoille, Fabien Rollot, et al. · JAMA Neurology · 18
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis
2025 · Antoine Gavoille, Emmanuelle Leray, et al. · Neurology · 15
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis
2025 · Marie Mainguy, Romain Casey, et al. · Neurology Neuroimmunology & Neuroinflammation · 13
PDF
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis
2025 · Camille Robin, Fabien Rollot, et al. · Neurology · 12
Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis
2026 · Fabien Rollot, Romain Casey, et al. · Brain · 8
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study
2024 · Marion Hay, Fabien Rollot, et al. · Neurology · 7
Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
2025 · Alexandra Garcia, Stephane Rodriguez, et al. · Annals of Clinical and Translational Neurology · 6
PDF
LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France
2025 · Jérôme de Sèze, Pierre Labauge, et al. · Advances in Therapy · 6
PDF
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study
2025 · Mikael Cohen, Fabien Rollot, et al. · European Journal of Neurology · 4
PDF
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis
2025 · Antoine Gavoille, Mikail Nourredine, et al. · Journal of Neurology Neurosurgery & Psychiatry · 3
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study
2026 · Izanne Roos, Sifat Sharmin, et al. · CNS Drugs · 1
PDF
Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials
2025 · Antoine Gavoille, Stanislas Demuth, et al. · medRxiv · 1
PDF
Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack
2026 · Manon Rival, Fabien Rollot, et al. · European Journal of Neurology
PDF
Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data
2026 · Chao Zhu, Sandra Vukusic, et al. · Journal of Neurology Neurosurgery & Psychiatry
Anti‐ CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis
2026 · Alexia Moukhine, Fabien Rollot, et al. · Annals of Clinical and Translational Neurology
PDF
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
2026 · Izanne Roos, Sifat Sharmin, et al. · Journal of Neurology Neurosurgery & Psychiatry
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis
2026 · Antoine Gavoille, Anne Kerbrat, et al. · Neurology
External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database
2026 · Laure Carcaillon-Bentata, Abdelilah Abouelfath, et al. · Multiple Sclerosis and Related Disorders
PDF
Genetic architecture of Multiple Sclerosis patients in the French national OFSEP-HD cohort
2025 · Julien Paris, Nayane S.B. Silva, et al. · medRxiv
PDF
Is there therapeutic inertia in women with MS?
2024 · Gavoille, Antoine, Leray, Emmanuelle, et al. · HAL
Highly effective therapies as first-line treatments for pediatric onset multiple sclerosis in a French nationwide cohort
2023 · Benallegue, Naïl, Rollot, Fabien, et al. · HAL
Silent Progression Activity Monitoring in MS despite an early highly active treatment: the SPAM study
2023 · Cohen, Mikael, Rollot, Fabien, et al. · HAL
Works count: 26
Citation count: 242
H-index: 8
I10-index: 7
Year
Topic
Type